In-Person Access Only | 4.50 Earn CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The First Annual DEBATING HEMATOLOGY Symposium will bring together nationally recognized leaders in malignant hematology for an engaging, evidence-based forum focused on the most debated topics across hematologic cancers. Through a series of structured debates, expert faculty will examine evolving standards of care, emerging therapeutic approaches, biomarker-driven treatment decisions, and sequencing strategies in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), multiple myeloma, chronic myeloid leukemia (CML), and myeloproliferative neoplasms (MPNs). Designed to challenge conventional thinking and foster meaningful discussion, the symposium will provide attendees with balanced perspectives, practical clinical insights, and actionable strategies for incorporating the latest evidence into hematology practice.
Conference Agenda
Friday, March 5, 2027
Program Chairs:
Chadi Nabhan, MD, MBA, FACP
3:00 PM
Arrival, Networking, and Registration
4:00 PM
Breakout Focus Groups
5:30 PM
Networking Reception
6:30 PM
Faculty Dinner
Saturday, March 6, 2027
7:30 AM
Coffee and Networking
8:00 AM
Welcome and Opening Remarks
Lymphoid Malignancies
8:15 AM
Debate 1: CLL
Time limited therapy is the standard: Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center
Continuous therapy is the standard: Alan Skarbnik, MD | Novant Health
8:45 AM
Debate 2: DLBCL front-line management
Progress made but R-Chop remains the standard: Sonali Smith, MD | University of Chicago
Progress made but R-Chop is no longer the standard: Reem Karmali, MD | Robert H. Lurie Comprehensive Cancer Center
9:15 AM
Snack and Coffee Break
9:45 AM
Non-CME Breakfast
10:30 AM
Networking Break
11:00 AM
Debate 3: MRD and ctDNA are ready for primetime in lymphoma
Yes: Joanna Rhodes, MD, MSCE | Rutgers Cancer Institute
No: Pallawi Torka, MD, MSK | Memorial Sloan Kettering Cancer Center
Myeloid Malignancies
11:30 AM
Debate 4: Front-Line AML
7+3 remains standard in fit patients: Hagop Kantarjian, MD | MD Anderson Cancer Center
Moving away from 7+3 for all: Uma Borate, MBBS | Ohio State University
12:00 PM
Debate 5: ALL
No more chemotherapy in front-line: Elias Jabbour, MD | MD Anderson Cancer Center
We still need chemotherapy in front-line: Bijal Shah, MD, MS | Moffitt Cancer Center
12:30 PM
Debate 6: MDS
Low-risk disease needs immediate therapy: Rami Komrokji, MD | Moffitt Cancer Center
We can watch and wait for low-risk disease: Amer Zeidan, MD | Yale Cancer Center
1:00 PM
Lunch and Exhibits
1:30 PM
Non-CME Lunch presented by Lily Hematology
2:15 PM
Networking, Housekeeping Notes and Survey
Myeloma and MPNs
2:45 PM
Debate 7: Front-Line Myeloma
MRD must guide therapy in front-line: Malin Hultcrantz, MD, PhD | Memorial Sloan Kettering Cancer Center
Front-line therapy is standardized and no need for MRD: Ajay Nooka, MD | Emory University
3:15 PM
Debate 8:CART in Myeloma
CART then bispecifics in relapsed myeloma: Natalia Neparidze, MD | Yale Cancer Center
Bispecific then CART in relapsed myeloma: Noopur Raje, MD | Massachusetts General Hospital
3:45 PM
Debate 9: Is Ruxolitinib Still the Default JAK Inhibitor in MF?
YES: It is the benchmark first-line therapy: Jamile Shammo, MD | Northwestern
NO: One size doesn't fit all: John Mascarenhas, MD | Icahn School of Medicine at Mount Sinai
4:15 PM
Debate 10: Selecting front-line therapy for CML
New generation TKI’s: Larry Cripe, MD | Indiana University
Old generation: Michael Mauro, MD | Memorial Sloan Kettering Cancer Center
4:45 PM
Concluding Remarks
5:00 PM
Sponsored Focus Group Opportunities
6:00 PM
ADJOURN
Agenda Subject To Change. All times are CST.
-
-
-
Complimentary registration for healthcare professionals
Expert debates on the most controversial and practice-changing topics in malignant hematology
Balanced, evidence-based perspectives from nationally recognized hematology experts
Practical clinical insights to support real-world treatment decision-making across hematologic malignancies
Interactive discussion and networking with faculty, peers, and industry partners
The latest advances in targeted therapies, immunotherapy, cellular therapies, precision medicine, and clinical research in hematology.